Licogliflozin is a dual inhibitor of Sodium/glucose cotransporters SGLT1 and SGLT2 with a higher selectivity for SGLT2 (in vitro IC₅₀ values of 20.6 and 0.58 nM, respectively). It causes a reduction in body weight from baseline versus placebo after 24 weeks (50 mg twice daily). However, the percent decreases were numerically small (<5%). Higher doses of licogliflozin also reduce waist circumference, fasting plasma glucose, hemoglobin A1c (HbA1c), systolic blood pressure and triglycerides. It increases HDL cholesterol and 24‐hour urinary glucose excretion.